Dalcetrapib, a cholesteryl ester transfer protein modulator

Safety, Tolerability and Pharmacokinetics of Dalcetrapib Following Single and Multiple Ascending Doses in Healthy Subjects

(2013) Michael Derks et al.   CLINICAL DRUG INVESTIGATION

Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial

(2012) Thomas F. Lüscher et al.   EUROPEAN HEART JOURNAL

Effect of dalcetrapib, a CETP modulator, on non-cholesterol sterol markers of cholesterol homeostasis in healthy subjects

(2011) Eric J. Niesor et al.   ATHEROSCLEROSIS

Effects of Food Intake on the Pharmacokinetic Properties of Dalcetrapib: Findings From Three Phase I, Single-Dose Crossover Studies in Healthy Volunteers

(2011) Michael Derks et al.   CLINICAL THERAPEUTICS

Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism

(2011) Eric J. Niesor   CURRENT OPINION IN LIPIDOLOGY

Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk

(2011) A. F. H. Stalenhoef et al.   DIABETES OBESITY & METABOLISM

Anacetrapib, a cholesteryl ester transfer protein inhibitor

(2011) Amanda J Hooper et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial

(2011) Zahi A Fayad et al.   LANCET

Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

Lack of clinically relevant drug-drug interactions when dalcetrapib is co-administered with ezetimibe

(2010) Michael Derks et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Cholesteryl Ester Transfer Protein Inhibition in Cardiovascular Risk Management: Ongoing Trials will End the Confusion

(2010) Paul J. W. H. Kappelle et al.   Cardiovascular Therapeutics

Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial

(2010) Evan A. Stein et al.   EUROPEAN HEART JOURNAL

Lack of effect of dalcetrapib on QT interval in healthy subjects following multiple dosing

(2010) Michael Derks et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

No clinically relevant drug–drug interactions when dalcetrapib is co-administered with atorvastatin

(2010) Michael Derks et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Coadministration of Dalcetrapib With Pravastatin, Rosuvastatin, or Simvastatin: No Clinically Relevant Drug-Drug Interactions

(2010) Michael Derks et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels

(2010) Roger G Clerc et al.   JOURNAL OF HYPERTENSION

Biochemical characterization of cholesteryl ester transfer protein inhibitors

(2010) Mollie Ranalletta et al.   JOURNAL OF LIPID RESEARCH

Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport

(2010) Eric J. Niesor et al.   JOURNAL OF LIPID RESEARCH

Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome

(2009) Gregory G. Schwartz et al.   AMERICAN HEART JOURNAL

Safety and Tolerability of Dalcetrapib††Conflicts of interest: Dr. Stein has received grants for studies of lipid-modifying agents, has received consulting fees and honoraria for professional input regarding agents to modify lipid profile, and/or has delivered lectures for the American Association for Clinical Chemistry, Washington, District of Columbia; Abbott Laboratories, Abbott Park, Illinois; AstraZeneca, Wilmington, Delaware; the United States Food and Drug Administration, Washington, District of Columbia; F. Hoffmann-La Roche Ltd., Basel, Switzerland; Isis Pharmaceuticals, Inc., Carlsbad, California; Merck & Co., Whitehouse Station, New Jersey; the National Lipid Association, Jacksonville, Florida; Novartis International AG, Basel Switzerland; Reliant Pharmaceuticals, Inc., Liberty Corner, New Jersey; Daiichi Sankyo Co., Ltd., Tokyo, Japan; Schering-Plough Corporation, Kenilworth, New Jersey; Takeda Pharmaceutical Company Ltd., Osaka, Japan; and Wyeth, Madison, New Jersey. Dr. Stroes has received consulting fees and honoraria from F. Hoffmann-La Roche Ltd. and Novartis International AG. Dr. Steiner has received consulting fees and honoraria from F. Hoffmann-La Roche Ltd.; Solvay, Brussels, Belgium; Ethypharm S.A., Saint-Cloud, France; and Merck Frosst Canada Ltd. (Kirkland, Quebec, Canada)/Schering-Plough Corporation. Dr. Buckley has received research grants from AstraZeneca; Merck Sharp & Dohme, Dublin, Ireland; and Pfizer, Inc., New York, New York. Dr. Buckley has received honoraria and consulting fees and/or delivered lectures for AstraZeneca; Bristol-Myers Squibb, New York, New York; F. Hoffmann-La Roche Ltd.; Novartis International AG; Pfizer, Inc.; and Sanofi-Aventis, Paris, France. Dr. Capponi has received consulting fees and honoraria from F. Hoffmann-La Roche Ltd. Dr. Burgess is an employee of Hoffmann-La Roche Inc., Nutley, New Jersey. Drs. Niesor and Kallend are employees of F. Hoffmann-La Roche Ltd. Dr. Kastelein has received research grants, honoraria, or consulting fees for professional input and/or has delivered lectures for Pfizer, Inc.; Merck Sharp & Dohme; F. Hoffmann-La Roche Ltd.; Novartis International AG; Isis Pharmaceuticals, Inc.; Kowa Pharmaceutical Company Ltd., Nagoya, Japan; Schering-Plough Corporation; and AstraZeneca.

(2009) Evan A. Stein et al.   AMERICAN JOURNAL OF CARDIOLOGY

Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats

(2009) ESG Stroes et al.   BRITISH JOURNAL OF PHARMACOLOGY

Association of Circulating Cholesteryl Ester Transfer Protein Activity With Incidence of Cardiovascular Disease in the Community

(2009) Ramachandran S. Vasan et al.   CIRCULATION

A single-center, open-label, one-sequence study of dalcetrapib coadministered with ketoconazole, and an in vitro study of the S-methyl metabolite of dalcetrapib

(2009) Michael Derks et al.   CLINICAL THERAPEUTICS

In vitroandin vivoassessment of the effect of dalcetrapib on a panel of CYP substrates

(2009) Michael Derks et al.   CURRENT MEDICAL RESEARCH AND OPINION